Serological immunoreactivity against colon cancer proteome varies upon disease progression.

De Monte L., Sanvito F., Olivier S., Viganò F., Doglioni C., Frasson M., Braga M., Bachi A., Dellabona P., Protti M.P., Alessio M.
J Proteome Res (In press)

Sera from colon carcinoma patients were used to identify tumor-associated antigens (TAAs) by screening tumor proteome resolved by 2D electrophoresis. A panel of six TAAs eliciting a serological immune response in colorectal cancer was identified, showing a modification in antigen recognition by B cells in patients as a function of colon cancer progression. The expression of these proteins was either confined or increased in tumor as compared to normal mucosa.

URL: http://pubs.acs.org/doi/abs/10.1021/pr070360m

Pub Med: http://www.ncbi.nlm.nih.gov/pubmed/18179166

created over 15 years ago (2 March 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]